Literature DB >> 31468377

ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilization.

Sharmila Dorbala1, Yukio Ando2, Sabahat Bokhari3, Angela Dispenzieri4, Rodney H Falk5, Victor A Ferrari6, Marianna Fontana7, Olivier Gheysens8, Julian D Gillmore7, Andor W J M Glaudemans9, Mazen A Hanna10, Bouke P C Hazenberg11, Arnt V Kristen12, Raymond Y Kwong5, Mathew S Maurer3, Giampaolo Merlini13,14, Edward J Miller15, James C Moon7, Venkatesh L Murthy16, C Cristina Quarta7, Claudio Rapezzi17, Frederick L Ruberg18, Sanjiv J Shah19, Riemer H J A Slart9, Hein J Verberne20, Jamieson M Bourque21.   

Abstract

Cardiac amyloidosis is emerging as an underdiagnosed cause of heart failure and mortality. Growing literature suggests that a noninvasive diagnosis of cardiac amyloidosis is now feasible. However, the diagnostic criteria and utilization of imaging in cardiac amyloidosis are not standardized. In this paper, Part 2 of a series, a panel of international experts from multiple societies define the diagnostic criteria for cardiac amyloidosis and appropriate utilization of echocardiography, cardiovascular magnetic resonance imaging, and radionuclide imaging in the evaluation of patients with known or suspected cardiac amyloidosis.

Entities:  

Keywords:  Appropriate use; Cardiac amyloidosis; Diagnosis; Expert consensus; Multimodality

Year:  2020        PMID： 31468377     DOI： 10.1007/s12350-019-01761-5

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


  34 in total

1.  ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.

Authors:  W Gregory Hundley; David A Bluemke; J Paul Finn; Scott D Flamm; Mark A Fogel; Matthias G Friedrich; Vincent B Ho; Michael Jerosch-Herold; Christopher M Kramer; Warren J Manning; Manesh Patel; Gerald M Pohost; Arthur E Stillman; Richard D White; Pamela K Woodard
Journal:  Circulation       Date:  2010-05-17       Impact factor: 29.690

Review 2.  2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: a joint report of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Foundation Appropriate Use Criteria Task Force.

Authors:  Manesh R Patel; Richard D White; Suhny Abbara; David A Bluemke; Robert J Herfkens; Michael Picard; Leslee J Shaw; Marc Silver; Arthur E Stillman; James Udelson
Journal:  J Am Coll Cardiol       Date:  2013-04-23       Impact factor: 24.094

3.  2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Rick A Nishimura; Catherine M Otto; Robert O Bonow; Blase A Carabello; John P Erwin; Robert A Guyton; Patrick T O'Gara; Carlos E Ruiz; Nikolaos J Skubas; Paul Sorajja; Thoralf M Sundt; James D Thomas
Journal:  Circulation       Date:  2014-03-03       Impact factor: 29.690

4.  Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System.

Authors:  Martha Grogan; Christopher G Scott; Robert A Kyle; Steven R Zeldenrust; Morie A Gertz; Grace Lin; Kyle W Klarich; Wayne L Miller; Joseph J Maleszewski; Angela Dispenzieri
Journal:  J Am Coll Cardiol       Date:  2016-09-06       Impact factor: 24.094

Review 5.  How I manage monoclonal gammopathy of undetermined significance.

Authors:  Ronald S Go; S Vincent Rajkumar
Journal:  Blood       Date:  2017-11-28       Impact factor: 22.113

6.  Normal left ventricular myocardial thickness for middle-aged and older subjects with steady-state free precession cardiac magnetic resonance: the multi-ethnic study of atherosclerosis.

Authors:  Nadine Kawel; Evrim B Turkbey; J Jeffrey Carr; John Eng; Antoinette S Gomes; W Gregory Hundley; Craig Johnson; Sofia C Masri; Martin R Prince; Rob J van der Geest; João A C Lima; David A Bluemke
Journal:  Circ Cardiovasc Imaging       Date:  2012-06-15       Impact factor: 7.792

7.  Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

Authors:  Giovanni Palladini; Carlo Campana; Catherine Klersy; Alessandra Balduini; Giovanbattista Vadacca; Vittorio Perfetti; Stefano Perlini; Laura Obici; Edoardo Ascari; Gianvico Melzi d'Eril; Remigio Moratti; Giampaolo Merlini
Journal:  Circulation       Date:  2003-04-28       Impact factor: 29.690

8.  Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.

Authors:  Angela Dispenzieri; Morie A Gertz; Robert A Kyle; Martha Q Lacy; Mary F Burritt; Terry M Therneau; Philip R Greipp; Thomas E Witzig; John A Lust; S Vincent Rajkumar; Rafael Fonseca; Steven R Zeldenrust; Christopher G A McGregor; Allan S Jaffe
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

9.  Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.

Authors:  Adam Castaño; David L Narotsky; Nadira Hamid; Omar K Khalique; Rachelle Morgenstern; Albert DeLuca; Jonah Rubin; Codruta Chiuzan; Tamim Nazif; Torsten Vahl; Isaac George; Susheel Kodali; Martin B Leon; Rebecca Hahn; Sabahat Bokhari; Mathew S Maurer
Journal:  Eur Heart J       Date:  2017-10-07       Impact factor: 29.983

10.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.

Authors:  Julian D Gillmore; Mathew S Maurer; Rodney H Falk; Giampaolo Merlini; Thibaud Damy; Angela Dispenzieri; Ashutosh D Wechalekar; John L Berk; Candida C Quarta; Martha Grogan; Helen J Lachmann; Sabahat Bokhari; Adam Castano; Sharmila Dorbala; Geoff B Johnson; Andor W J M Glaudemans; Tamer Rezk; Marianna Fontana; Giovanni Palladini; Paolo Milani; Pierluigi L Guidalotti; Katarina Flatman; Thirusha Lane; Frederick W Vonberg; Carol J Whelan; James C Moon; Frederick L Ruberg; Edward J Miller; David F Hutt; Bouke P Hazenberg; Claudio Rapezzi; Philip N Hawkins
Journal:  Circulation       Date:  2016-04-22       Impact factor: 29.690
View more
  21 in total

1.  Native T1 Mapping, Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis: A Meta-Analysis.

Authors:  Jonathan A Pan; Matthew J Kerwin; Michael Salerno
Journal:  JACC Cardiovasc Imaging       Date:  2020-06

2.  Racial and Ethnic Disparities in Transthyretin Cardiac Amyloidosis.

Authors:  Gabriela Spencer-Bonilla; Joyce N Njoroge; Keon Pearson; Ronald M Witteles; Mandar A Aras; Kevin M Alexander
Journal:  Curr Cardiovasc Risk Rep       Date:  2021-04-04

Review 3.  KSNM60 in Cardiology: Regrowth After a Long Pause.

Authors:  Sang-Geon Cho; Eun Jung Kong; Won Jun Kang; Jin Chul Paeng; Hee-Seung Henry Bom; Ihnho Cho
Journal:  Nucl Med Mol Imaging       Date:  2021-06-08

4.  Potential clinical relevance of cardiac magnetic resonance to diagnose cardiac light chain amyloidosis.

Authors:  Zsofia Dohy; Liliana Szabo; Zoltan Pozsonyi; Ibolya Csecs; Attila Toth; Ferenc Imre Suhai; Csilla Czimbalmos; Andrea Szucs; Anna Reka Kiss; David Becker; Bela Merkely; Hajnalka Vago
Journal:  PLoS One       Date:  2022-06-13       Impact factor: 3.752

5.  Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis.

Authors:  Golnaz Roshankar; Geneva C White; Sebastien Cadet; Nowell M Fine; Denise Chan; James A White; Victor Jimenez-Zepeda; Piotr J Slomka; Robert J H Miller
Journal:  J Nucl Cardiol       Date:  2021-10-03       Impact factor: 3.872

6.  Ala97Ser transthyretin amyloidosis-associated polyneuropathy, clinical and neurophysiological profiles in a Thai cohort.

Authors:  Nath Pasutharnchat; Chamaiporn Taychargumpoo; Yongkasem Vorasettakarnkij; Jakkrit Amornvit
Journal:  BMC Neurol       Date:  2021-05-22       Impact factor: 2.474

7.  Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis.

Authors:  Robert J H Miller; Sebastien Cadet; Darren Mah; Payam Pournazari; Denise Chan; Nowell M Fine; Daniel S Berman; Piotr J Slomka
Journal:  J Nucl Cardiol       Date:  2021-03-10       Impact factor: 5.952

Review 8.  Multimodality Imaging in the Evaluation and Management of Cardiac Amyloidosis.

Authors:  Yiu Ming Khor; Sarah Cuddy; Rodney H Falk; Sharmila Dorbala
Journal:  Semin Nucl Med       Date:  2020-02-09       Impact factor: 4.802

9.  Diagnosis of Amyloidosis: A Survey of Current Awareness and Clinical Challenges Among Cardiologists in Switzerland.

Authors:  Dennis Mircsof
Journal:  Cardiol Ther       Date:  2020-01-20

10.  Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation- (4Is) related cardiovascular diseases: a joint collaboration of the EACVI and the EANM: summary.

Authors:  Riemer H J A Slart; Andor W J M Glaudemans; Olivier Gheysens; Mark Lubberink; Tanja Kero; Marc R Dweck; Gilbert Habib; Oliver Gaemperli; Antti Saraste; Alessia Gimelli; Panagiotis Georgoulias; Hein J Verberne; Jan Bucerius; Christoph Rischpler; Fabien Hyafil; Paola A Erba
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2020-12-01       Impact factor: 6.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.